Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.
Key Details
- 1Harrison.ai received three FDA breakthrough device designations.
- 2One designation is for a triage/prioritization AI solution for obstructive hydrocephalus.
- 3The solution is among only 13% of FDA breakthrough devices to achieve 510(k) marketing authorization.
- 4It is one of only two radiology FDA breakthrough devices to become eligible for Medicare’s NTAP.
- 5The FDA program aims to speed up innovation and clinical access to critical devices.
Why It Matters
FDA breakthrough status highlights a product's potential to address unmet clinical needs, and rapid regulatory pathways can accelerate adoption in radiology practice. Harrison.ai's achievement signals growing validation and support for advanced imaging AI in critical care.
Source
Radiology Business
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
Study Finds Disparities in Access to Stroke Imaging AI Tools
Research shows access to AI stroke detection tools is concentrated in resource-rich hospitals despite Medicare incentives.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.